Stock Analiz

Prothena Corp. Public Ltd. Co. PRTA

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$8.16Market cap $419M
Open the interactive analysis →

Prothena Corp. Public Ltd. Co. (PRTA) is a healthcare company listed in the US with a market value of about $419M. In the twelve months to September 30, 2026 it had revenue of $53M and net income of -$24M, a net margin of -45.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 63% a year, a 5-year average ROIC of -25%.

About Prothena Corp. Public Ltd.

Prothena Corp. Public Ltd. is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $51M in 2014 to $10M in 2025, a decline of about 14.0% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 14% over three years (dilution for shareholders). It spends 1393% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.9
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-7.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-92.8%
Revenue growth (5 yrs, per year)62.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-591.1%
ROIC (5-yr avg.)-24.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$53M$10M$135M$91M$54M$201M$853000$814000$955000$28M$1M
Net income-$24M-$244M-$122M-$147M-$117M$67M-$111M-$78M-$156M-$153M-$160M
Free cash flow-$31M-$164M-$150M-$134M-$109M$93M-$80M-$53M———
EPS (diluted)$-0.45$-4.53$-2.27$-2.76$-2.47$1.38$-2.78$-1.95$-3.93$-4.07$-4.66
Net margin-45.4%-2520.6%-90.5%-160.9%-217.0%33.4%-13029.8%-9542.6%-16297.9%-556.8%-15176.1%
ROIC—-58.7%-29.5%-30.5%-19.5%14.0%-55.7%-22.9%-49.0%-37.1%-34.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $21.40, 162% above the current price; targets range from $8.00 to $36.00; the consensus rating is “Buy”; expected EPS is $0.66 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Prothena Corp. Public Ltd. pay a dividend?

Not currently.

Is Prothena Corp. Public Ltd. a good stock to buy?

We do not give buy or sell advice. Prothena Corp. Public Ltd. scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.